On August 10, 2026, a small Vancouver biotech announced that its experimental hot-flash drug had hit the numbers. By the next morning the stock was up roughly 34%, analysts were raising price targets, and by the end of the week the company had raised $200 million in an oversubscribed offering Reported: BioSpace Established: AbCellera. Every woman who's ever typed "is there a new hot flash drug" into a search bar felt that stock move in her chest.
Here's the part the market news doesn't tell you: it's not a pill, it's an injection, and it's years away from your medicine cabinet. This article is the honest version of the headline.
What actually happened
AbCellera's ABCL-635 is an investigational antibody for moderate-to-severe vasomotor symptoms - hot flashes and night sweats - due to menopause. On August 10 the company announced positive top-line Phase 2 results: a significant reduction in both the frequency and severity of vasomotor symptoms, with a favorable tolerability profile Established: AbCellera. Trade-press coverage put the headline number at 83% reduction versus baseline Reported: BioSpace.
That number is doing a lot of work, so let's be precise about what it is: a company-reported, versus-baseline figure from a press release, relayed by trade media, not yet peer-reviewed, not yet placebo-adjusted the way FDA trials are judged. Impressive signal. Not proof. We'll come back to that.
What ABCL-635 actually is
The pills you've heard about - Veozah and Lynkuet - work by blocking neurokinin-3 receptors, a protein on neurons in the hypothalamus that help regulate body temperature. When estrogen drops in menopause, that temperature-regulation circuit runs hot, and NK3 blockers turn the thermostat back down. That's the whole non-hormonal revolution in one sentence.
ABCL-635 is the same idea with a different tool. Instead of a small molecule pill that blocks the receptor, it's an antibody that binds NK3R directly - the first AbCellera program to come out of its GPCR and ion-channel platform Established: AbCellera. It's given by subcutaneous injection. The company's stated design goals, in its own words: efficacy comparable to the small-molecule drugs, a differentiated safety profile without the need for liver enzyme monitoring, and a convenient once-monthly self-injection.
Read that again: without the need for liver enzyme monitoring. That's the company pointing at the exact burden that made Veozah's boxed warning famous - the blood tests before starting, monthly for three months, then at months 6 and 9, and the stop-on-symptom list you should have screenshotted Established: FDA. A monthly injection that skips the lab schedule is a genuinely appealing pitch. It's also a pitch - those goals are design ambitions until Phase 3 and an FDA review prove them.
The class, in one table
| | Veozah (fezolinetant) | Lynkuet (elinzanetant) | ABCL-635 | |---|---|---|---| | What it is | NK3 small-molecule pill | NK3 small-molecule pill | NK3-receptor antibody injection | | Status | FDA-approved May 2023 | FDA-approved Oct 24, 2025 | Phase 2 (top-line Aug 2026) | | Availability | Available now | US availability expected Nov 2026 Reported: NYT | Years away | | Dosing | Daily pill | Two capsules at bedtime | Once-monthly injection (design goal) | | Liver monitoring | Yes - boxed warning, blood-test schedule | Per its label | Not required by design (unproven) |
They're not rivals. They're the same family at three different ages: the kid in school, the recent graduate, and the baby who hasn't been born yet.
What Phase 2 actually means
This is the part every headline skips. Phase 2 is where you learn whether a drug does something. It is not where you learn whether a drug will exist.
Consider the actual trial: NCT07118891, a Phase 1/2 study, 136 participants, currently listed as active and not recruiting Established: ClinicalTrials.gov. That's a small, early-stage dataset - appropriate for what it is, nowhere near the scale of the pivotal trials that brought Veozah and Lynkuet to approval. The 83% figure is versus baseline, which measures improvement from each participant's own starting point. FDA trials are judged on placebo-adjusted differences, which are always smaller numbers and always the honest ones. Until ABCL-635 runs a Phase 3 against placebo, we do not know how its efficacy stacks up against the drugs that already exist.
And the market knows it's early too - which is why the stock story is a stock story. A $200 million raise off a Phase 2 readout is how an early-stage biotech funds the long road ahead, not evidence that the road is short Established: AbCellera. By the August 13 close, ABCL shares sat at $10.97, up over 200% year to date - a 52-week high for a company whose drug is still years from a pharmacy shelf. The market prices possibility. Your body can't wait on possibility.
What to do now
The honest answer, the one that doesn't sell clicks: don't wait. The pipeline is worth watching, and we'll keep watching it - that's what we do. But "a new drug is coming" is news, not a treatment plan.
If you're in the non-hormonal lane because hormones aren't an option for you, the approved choices exist right now, and the blood-test schedule isn't a dealbreaker, it's a safety system. Our full Veozah vs Lynkuet breakdown has the details, including the exact monitoring schedule and the questions to bring to your prescriber. If the options on the market haven't worked for you, that's a conversation for your clinician about what's left - not a countdown to a press release.
And for the nights between now and whenever ABCL-635 shows up: the 60-second cool-down still works. It costs nothing and it doesn't require a Phase 3.
The next hot flash drug is coming. In the meantime, the next hot flash is coming too - and you've got options for that one that exist today.